U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Medical Devices
  3. Device Advice: Comprehensive Regulatory Assistance
  4. How to Study and Market Your Device
  5. Premarket Submissions: Selecting and Preparing the Correct Submission
  6. Biocompatibility Assessment Resource Center
  7. Biocompatibility Evaluation Endpoints by Contact Duration Periods
  1. Biocompatibility Assessment Resource Center

Biocompatibility Evaluation Endpoints by Contact Duration Periods

The following is a framework for the development of a biocompatibility evaluation and is not a checklist for testing.

For particular medical devices, different biological endpoints may require evaluation, including either additional or fewer endpoints than indicated. If it is unclear in which category a device falls, the FDA recommends consulting device-specific guidances or contacting the appropriate Center and review division for more information.

For example, the FDA has historically considered devices used to drain fluids (such as Foley catheters) as externally communicating devices rather than as surface devices contacting mucosal membranes.

Note: On this page, FDA's Biocompatibility Guidance on Use of ISO 10993-1 refers to Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process." The content on this page comes from this guidance, unless otherwise noted.

Device categorization information can be obtained informally via email, or as a part of the Q-Submission process. Refer to the FDA's guidance document, Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program: Guidance for Industry and Food and Drug Administration Staff.

Tables: Each of the tables on this page lists biological effects for contact duration periods by specific medical device categorization and nature of body contact. The contact duration periods are:

  • Limited: Less than or equal to 24 hours
  • Prolonged: Greater than 24 hours to 30 days
  • Long term / Permanent: More than 30 days

Within each table, endpoints are listed by:

  • Surface Device
    • Intact Skin
    • Mucosal Membrane
    • Breached or Compromised Surface
  • External Communicating Device
    • Blood Path, Indirect
    • Tissue/Blood/Dentin
    • Circulating Blood
  • Implant Device
    • Tissue/Bone
    • Blood

Endpoints for Consideration: The endpoints for consideration listed in the tables include:

  • ISO 10993-1 recommended endpoints for consideration
  • Additional FDA recommended endpoints for consideration

Refer to FDA's Biocompatibility Guidance on Use of ISO 10993-1, Attachment A for details on which endpoints are included in ISO 10993-1 recommendations and which are additional FDA recommended endpoints.

Important: All recommended endpoints should be addressed in the biological safety evaluation, either through the use of existing data, additional endpoint-specific testing, or a rationale* for why the endpoint does not require additional assessment.

* For certain devices that contact intact skin, specific information may be provided in premarket submissions instead of a biocompatibility evaluation to address the applicable endpoints. Refer to FDA's Biocompatibility Guidance on Use of ISO 10993-1, Attachment G for more information on this policy.

Other endpoints (not included in the tables) to be addressed are:

  • Reproductive and developmental toxicity: Should be addressed for novel materials, materials with a known reproductive or developmental toxicity, devices with relevant target populations (for example, pregnant women), and/or devices where there is the probability for local presence of device materials in the reproductive organs.
  • Degradation information: Should be provided for any devices, device components, or materials remaining in contact with tissue that are intended to degrade.

Limited Contact: Surface Device

Biological Effect

Intact Skin

Mucosal Membrane

Breached or Compromised Surface

Cytotoxicity

Sensitization

Irritation or Intracutaneous Reactivity

Acute Systemic Toxicity

 

 

Material-Mediated Pyrogenicity

 

 

Notes:

  • For certain devices that contact intact skin, you may not need to assess these endpoints if your device or components are made from common materials, as identified in Attachment G of the FDA's Biocompatibility Guidance on Use of ISO 10993-1.
  • Other endpoints you may need to address: Reproductive and development toxicity, degradation information.
  • If novel materials or manufacturing processes are used, you may need to do additional biocompatibility evaluations.

Limited Contact: External Communicating Device


Biological Effect

Blood Path, Indirect

Tissue/Bone/Dentin

Circulating Blood

Cytotoxicity

Sensitization

Irritation or Intracutaneous Reactivity

Acute Systemic Toxicity

Material-Mediated Pyrogenicity

Genotoxicity

 

 

✔ (see note)

Hemocompatibility

 

Notes:

  • Tissue includes tissue fluids and subcutaneous spaces.
  • Genotoxicity: For all devices used in extracorporeal circuits.
  • Other endpoints you may need to address: Reproductive and development toxicity, degradation information.
  • If novel materials or manufacturing processes are used, you may need to do additional biocompatibility evaluations.

Limited Contact: Implant Device

Biological Effect

Tissue/Bone

Blood

Cytotoxicity

Sensitization

Irritation or Intracutaneous Reactivity

Acute Systemic Toxicity

Material-Mediated Pyrogenicity

Genotoxicity

 

Implantation

 

Hemocompatibility

 

Notes:

  • Other endpoints you may need to address: Reproductive and development toxicity, degradation information.
  • If novel materials or manufacturing processes are used, you may need to do additional biocompatibility evaluations.

Prolonged Contact: Surface Device

Biological Effect

Intact Skin

Mucosal Membrane

Breached or Compromised Surface

Cytotoxicity

Sensitization

Irritation or Intracutaneous Reactivity

Acute Systemic Toxicity

 

Material-Mediated Pyrogenicity

 

Subacute/Subchronic Toxicity

 

Implantation

 

Notes:

  • For certain devices that contact intact skin, you may not need to assess these endpoints if your device or components are made from common materials, as identified in Attachment G of the FDA's Biocompatibility Guidance on Use of ISO 10993-1.
  • Other endpoints you may need to address: Reproductive and development toxicity, degradation information.
  • If novel materials or manufacturing processes are used, you may need to do additional biocompatibility evaluations.

Prolonged Contact: External Communicating Device

Biological Effect

Blood Path, Indirect

Tissue/Bone/Dentin

Circulating Blood

Cytotoxicity

Sensitization

Irritation or Intracutaneous Reactivity

Acute Systemic Toxicity

Material-Mediated Pyrogenicity

Subacute/Subchronic Toxicity

Genotoxicity

 

Implantation

 

Hemocompatibility

 

Notes:

  • Tissue includes tissue fluids and subcutaneous spaces.
  • Other endpoints you may need to address: Reproductive and development toxicity, degradation information.
  • If novel materials or manufacturing processes are used, you may need to do additional biocompatibility evaluations.

Prolonged Contact: Implant Device

Biological Effect

Tissue/Bone

Blood

Cytotoxicity

Sensitization

Irritation or Intracutaneous Reactivity

Acute Systemic Toxicity

Material-Mediated Pyrogenicity

Subacute/Subchronic Toxicity

Genotoxicity

Implantation

Hemocompatibility

 

Notes:

  • Tissue includes tissue fluids and subcutaneous spaces.
  • Other endpoints you may need to address: Reproductive and development toxicity, degradation information.
  • If novel materials or manufacturing processes are used, you may need to do additional biocompatibility evaluations.

Long Term / Permanent Contact: Surface Device

Biological Effect

Intact Skin

Mucosal Membrane

Breached or Compromised Surface

Cytotoxicity

Sensitization

Irritation or Intracutaneous Reactivity

Acute Systemic Toxicity

 

Material-Mediated Pyrogenicity

 

Subacute/Subchronic Toxicity

 

Genotoxicity

 

Implantation

 

Chronic Toxicity

 

Carcinogenicity

 

 

Notes:

  • For certain devices that contact intact skin, you may not need to assess these endpoints if your device or components are made from common materials, as identified in Attachment G of the FDA's Biocompatibility Guidance on Use of ISO 10993-1.
  • Other endpoints you may need to address: Reproductive and development toxicity, degradation information.
  • If novel materials or manufacturing processes are used, you may need to do additional biocompatibility evaluations.

Long Term / Permanent Contact: External Communicating Device

Biological Effect

Blood Path, Indirect

Tissue/Bone/Dentin

Circulating Blood

Cytotoxicity

Sensitization

Irritation or Intracutaneous Reactivity

Acute Systemic Toxicity

Material-Mediated Pyrogenicity

Subacute/Subchronic Toxicity

Genotoxicity

Implantation

Hemocompatibility

 

Chronic Toxicity

Carcinogenicity

Notes:

  • Tissue includes tissue fluids and subcutaneous spaces.
  • Other endpoints you may need to address: Reproductive and development toxicity, degradation information.
  • If novel materials or manufacturing processes are used, you may need to do additional biocompatibility evaluations.

Long Term / Permanent Contact: Implant Device

Biological Effect

Tissue/Bone

Blood

Cytotoxicity

Sensitization

Irritation or Intracutaneous Reactivity

Acute Systemic Toxicity

Material-Mediated Pyrogenicity

Subacute/Subchronic Toxicity

Genotoxicity

Implantation

Hemocompatibility

 

Chronic Toxicity

Carcinogenicity

Notes:

  • Tissue includes tissue fluids and subcutaneous spaces.
  • Other endpoints you may need to address: Reproductive and development toxicity, degradation information.
  • If novel materials or manufacturing processes are used, you may need to do additional biocompatibility evaluations.

 

Back to Top